Latest News & Features
Biotechnology
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned. 30 September 2019
Americas
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff. 30 September 2019
Big Pharma
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences. 30 September 2019
Biotechnology
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse. 30 September 2019
Biotechnology
There is no doubting the importance of next year’s CRISPR appeal, but any conclusions about the parties’ prior art have consequences for elsewhere too, say Catherine Coombes and Emma Longland of HGF. 30 September 2019
Biotechnology
The Actavis v ICOS UK Supreme Court judgment was a bitter pill to swallow, but is it really the end of dosage patents? Richard Wells and Stephanie Pilkington of Potter Clarkson review the situation. 30 September 2019
Americas
Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain. 30 September 2019
Americas
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement. 30 September 2019
Plant Varieties
The Delhi High Court has taken the unusual step of directing the IPAB to hear an urgent matter with the help of a technical expert from the Plant Varieties Protection Authority. Vidisha Garg of Anand and Anand reports. 30 September 2019
Big Pharma
Bringing a drug to market is costing companies under $2 billion for the first time in five years, according to a report from IP service provider Clarivate Analytics. 30 September 2019